Bipolar Disorder Clinical Trials in San Diego

View 16 new treatments for Bipolar Disorder in San Diego, CA, and other areas near me, such as Carlsbad, Chula Vista, El Cajon, Escondido, Oceanside and Vista. Every day, Power helps hundreds of bipolar patients connect with leading medical research.
View 15 trials in San Diego
Filter (15)

Lumateperone for Schizophrenia and Bipolar Disorder

Intra-Cellular Therapies Clinic, San Diego + 1 more

This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia or bipolar disorder.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

Cariprazine for Bipolar Disorder in Youth

AbbVie Clinic, San Diego + 1 more

This trial is testing the safety and effectiveness of Cariprazine for treating depressive episodes in children and teenagers with bipolar I disorder. The goal is to find out if Cariprazine can help young people with this condition. Cariprazine is an atypical antipsychotic recently approved for the treatment of depressive episodes in adults with bipolar I disorder.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
ABBVIE INC.
Study Director

Lumateperone for Pediatric Bipolar Depression

Intra-Cellular Therapies Clinic, San Diego + 1 more

This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team

Dexmedetomidine for Agitation in Schizophrenia and Bipolar Disorder

BioXcel Clinic, Oceanside + 3 more

In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Robert Risinger, MD
Study Chair

Cariprazine for Pediatric Schizophrenia

AbbVie Clinic, San Diego + 1 more

This trial is testing the safety and effectiveness of cariprazine in children and teens with schizophrenia, bipolar I disorder, or autism. The goal is to see if the medication is safe and beneficial for use in these young patients.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
ABBVIE INC.
Study Director

Lumateperone for Bipolar Mania

Intra-Cellular Therapies Clinic, Lemon Grove + 1 more

This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

BHV-7000 for Bipolar Disorder

Biohaven Clinic, Lemon Grove + 1 more

The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.
Recruiting
Phase 2 & 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team

BHV-7000 for Bipolar Disorder

Biohaven Clinic, Lemon Grove + 1 more

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.
Waitlist

No Placebo Trial

Phase 2
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

ALTO-100 for Bipolar Depression

Alto Neuroscience Clinic, Oceanside + 1 more

The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used adjunctively to a mood stabilizer, related to patient characteristics. Additionally, safety, tolerability, and efficacy will be assessed in a subsequent open label treatment period.Show More
Recruiting
Phase 2
Est. 6 - 12 Weeks
Mallory Loflin, PhD
Study Director

ABBV-932 for Bipolar Disorder

AbbVie Clinic, Oceanside + 1 more

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how safe and effective ABBV-932 is in treating participants with bipolar I or II disorder. ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Study doctors put participants in 1 of 4 groups, called treatment arms. There is a 1 in 4 chance that a participant will be assigned to placebo. Around 160 adult participants with bipolar I or II disorder will be enrolled in approximately 40 sites worldwide. Participants will receive oral capsules of ABBV-932 or matching placebo once daily for 6 weeks. The treatment period will be followed by a safety follow-up (SFU) period for 4 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.Show More
Recruiting
Phase 2
Est. 3 - 6 Weeks
ABBVIE INC.
Study Director
Page 1 of 2

Frequently Asked Questions

How much do bipolar clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do bipolar clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across bipolar trials in San Diego, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for bipolar patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in San Diego is research being conducted for bipolar?

In San Diego, clinical trials for bipolar are being conducted at a site in the central area, with approximately 2 trials ongoing.

What promising new drugs are being tested?

In San Diego, research for bipolar disorder includes treatments like Atypical Antipsychotics and Repetitive Transcranial Magnetic Stimulation. Specific interventions being studied are Cariprazine, Lumateperone, and VNS Therapy® System.